Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 1,069 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo, Cohort 3 Clear all
Completed Phase 3 Interventional

A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2

NCT06039449
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
VYD222 (pemivibart), Normal saline
Drug
Lead sponsor
Invivyd, Inc.
Industry
Eligibility
12 Years and older
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
18
States / cities
Fullerton, California • Long Beach, California • Rolling Hills Estates, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 18, 2026, 2:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval

NCT05924815
View directory record Official record
Conditions
Healthy Participants
Interventions
Aficamten, Aficamten-matching Placebo, Moxifloxacin
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 45 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 18, 2026, 2:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism

NCT02923115
View directory record Official record
Conditions
Pulmonary Embolism, Thrombotic Disease
Interventions
DS-1040b, Placebo, Enoxaparin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
15
States / cities
Mobile, Alabama • Beverly Hills, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 18, 2026, 2:49 AM EDT
Not listed Phase 1 Interventional

Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)

NCT04629105
View directory record Official record
Conditions
ARDS, Human, Covid19
Interventions
Longeveron Mesenchymal Stem Cells (LMSCs), Placebo
Biological · Other
Lead sponsor
Longeveron Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Miami, Florida • Baltimore, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 18, 2026, 2:49 AM EDT
Completed Phase 1 Interventional

Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500

NCT02107872
View directory record Official record
Conditions
Metabolic Disorders
Interventions
REGN1500, placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Oct 18, 2026, 2:49 AM EDT
Terminated Phase 2Phase 3 Interventional

Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

NCT05130866
View directory record Official record
Conditions
Neurofibromatosis Type 2
Interventions
REC-2282, Placebo
Drug
Lead sponsor
Recursion Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
14
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 18, 2026, 2:49 AM EDT
Recruiting Phase 2 Interventional

AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF

NCT06793371
View directory record Official record
Conditions
Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg), Placebo to match CK-4021586
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
40 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
26
States / cities
Fairhope, Alabama • Tucson, Arizona • Little Rock, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 18, 2026, 2:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device

NCT02146781
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
CryJ2-DNA-LAMP plasmid vaccine by intradermal injection, Saline Control
Biological · Other
Lead sponsor
Immunomic Therapeutics, Inc.
Industry
Eligibility
18 Years to 63 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 18, 2026, 2:49 AM EDT
Completed Phase 1 Interventional

A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus

NCT03235219
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
JNJ-64565111, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Chula Vista, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 18, 2026, 2:49 AM EDT
Terminated Phase 1 Interventional

A Study of Safety of PBCLN-003 Following Antibiotic Therapy in Subjects With C.Difficile-associated Diarrhea

NCT03793686
View directory record Official record
Conditions
Clostridium Difficile Diarrhea
Interventions
PBCLN-003, Placebo
Drug
Lead sponsor
Prolacta Bioscience
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Idaho Falls, Idaho
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 18, 2026, 2:49 AM EDT
Completed Phase 2 Interventional

Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus

NCT06152042
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
BMF-219
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
9
States / cities
North Miami Beach, Florida • Morehead City, North Carolina • Norman, Oklahoma + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 18, 2026, 2:49 AM EDT
Completed Phase 3 Interventional Results available

Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007

NCT03853798
View directory record Official record
Conditions
Pyruvate Kinase Deficiency
Interventions
Mitapivat
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
12
States / cities
Phoenix, Arizona • Oakland, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 18, 2026, 2:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Pharmacokinetic Study of Single-Ascending Doses of Intravenous Nafithromycin in Healthy Adult Subjects

NCT02770404
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Nafithromycin, Placebo
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 18, 2026, 2:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3009104(Baricitinib) for Healthy Subjects

NCT01247350
View directory record Official record
Conditions
Healthy Volunteer
Interventions
LY3009104, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 18, 2026, 2:49 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Safety, Immunogenicity and Efficacy Study of Inactivated Whole Cell Shigella Flexneri 2a Vaccine With and Without dmLT in Adults

NCT03038243
View directory record Official record
Conditions
Shigella Sonnei Dysenteries
Interventions
Shigella flexneri 2a whole cell (Sf2aWC) vaccine and double mutant E. coli heat labile toxin (dmLT), Shigella flexneri 2a whole cell (Sf2aWC) vaccine, Placebo
Biological · Other
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 18, 2026, 2:49 AM EDT
Completed Early Phase 1 Interventional

Study to Assess the Safety, Tolerability, PK and PD of ABX1100

NCT06109948
View directory record Official record
Conditions
Healthy, Late Onset Pompe Disease
Interventions
ABX1100 injection for IV infusion, Placebo injection for IV infusion
Drug
Lead sponsor
Aro Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Orange, California • St Louis, Missouri • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 18, 2026, 2:49 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Ad26.COV2.S in Adults (COVID-19)

NCT04436276
View directory record Official record
Conditions
Covid-19 Prevention
Interventions
Ad26.COV2.S, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
1,085 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
7
States / cities
San Diego, California • Melbourne, Florida • Peoria, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 18, 2026, 2:49 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

First in Human Phase 1 Ascending Dose Study of PanChol in Healthy Volunteers

NCT05657782
View directory record Official record
Conditions
Cholera, Cholera Vaccine Toxicity
Interventions
PanChol
Biological
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 18, 2026, 2:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase1 First in Human Ascending Dose Study to Evaluate the Safety and Tolerability of FC-12738 in Health Adults

NCT05978908
View directory record Official record
Conditions
Safety Issues, Tolerance
Interventions
FC-12738, Saline
Drug
Lead sponsor
Neurodegenerative Disease Research Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 18, 2026, 2:49 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis

NCT07558668
View directory record Official record
Conditions
Moderate to Severe Atopic Dermatitis
Interventions
SYX-5219 Oral Capsule
Drug
Lead sponsor
Sitryx Therapeutics Ltd
Industry
Eligibility
18 Years to 65 Years
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
6
States / cities
Arkansas City, Arkansas • Fremont, California • Plainfield, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 18, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Results available

A Study of TAK-071 in People With Parkinson Disease

NCT04334317
View directory record Official record
Conditions
Parkinson Disease, Healthy Participants
Interventions
TAK-071, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
40 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
21
States / cities
Garden Grove, California • Irvine, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 18, 2026, 2:49 AM EDT
Completed Phase 1 Interventional Results available

Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis

NCT04602390
View directory record Official record
Conditions
Multiple Sclerosis (MS), Relapsing Remitting Multiple Sclerosis
Interventions
ANK-700, Placebo
Drug
Lead sponsor
Anokion SA
Industry
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
15
States / cities
Cullman, Alabama • Phoenix, Arizona • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 18, 2026, 2:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects

NCT04788017
View directory record Official record
Conditions
Healthy Subjects
Interventions
Ziresovir, Placebo
Drug · Other
Lead sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 18, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Results available

Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

NCT01257204
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Placebo, Daclatasvir, Pegylated interferon alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Tulsa, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 18, 2026, 2:49 AM EDT